Takeda confirms acquisition of Nycomed for €9.6bn
This article was originally published in Scrip
Putting an end to speculation that has been swirling around for a week, Takeda has now confirmed that it will acquire Nycomed for €9.6 billion, in a deal that excludes the private Swiss group's US dermatology business.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.